RESUMO
AIM: To experimentally assess activity and safety of anti-anthrax intravenous immunoglobulin manufactured on standard technology. MATERIALS AND METHODS: Plasma from selected donors vaccinated with combined anthrax vaccine was tested by enzyme immunoassay. Samples of plasma with increased titer of anti-anthrax antibodies were merged in one manufacturing load and fractionated in ethanol at negative temperature according to standard technology. Formulation of intravenous immunoglobulin was manufactured according to standard technology of acid-enzyme hydrolysis. RESULTS: Proved medical technology of donors immune plasma fractionation provided 4 - 8-fold concentration of anti-anthrax antibodies. The finished product contained 5% of protein and was apyrogenic, non-toxic, thermostable, electrophoretically homogenous, had pH 6.65 and meet the requirements for manufacturing batches of human intravenous immunoglobulin. CONCLUSION: Protective effects of experimental human anti-anthrax immunoglobulin were comparable with control biological--equine anti-anthrax immunoglobulin for intramuscular use.
Assuntos
Antraz/terapia , Imunoglobulinas Intravenosas/uso terapêutico , Animais , Anticorpos Antibacterianos/sangue , Anticorpos Antibacterianos/imunologia , Especificidade de Anticorpos , Bacillus anthracis/imunologia , Fracionamento Químico , Humanos , CoelhosRESUMO
Time course of Marburg virus (strain Popp) accumulation and changes in hematological parameters were studied in aerosol infected M.rhesus monkeys. The lungs were the first organ in which the virus was detected after respiratory infection of monkeys. Four days after inoculation the virus was detected in the liver, spleen, blood, and thymus. Six days after inoculation the virus was present in virtually all organs and secretions. The period of fever was associated with manifest leukopenia in primates. Blood clotting time drastically increased by the moment of animal death.
Assuntos
Microbiologia do Ar , Doença do Vírus de Marburg/transmissão , Marburgvirus/patogenicidade , Animais , Fígado/virologia , Pulmão/virologia , Macaca mulatta , Doença do Vírus de Marburg/patologia , Doença do Vírus de Marburg/virologia , Marburgvirus/isolamento & purificação , Baço/virologia , Timo/virologia , ViremiaRESUMO
Marburg virus (strain Popp) was found to accumulate in various organs of guinea pigs after aerogenic infection. At the initial stage of the infection primary multiplication of the virus took place in the lungs. The presence of the virus in bronchopulmonary washings 2-3 days after infection, leukopenia and hyperthermia 4 days after infection are the earliest virological and clinical signs of disease in aerogenically infected guinea pigs.
Assuntos
Microbiologia do Ar , Líquido da Lavagem Broncoalveolar/virologia , Pulmão/virologia , Doença do Vírus de Marburg/fisiopatologia , Animais , Febre/fisiopatologia , Cobaias , Leucopenia/fisiopatologia , Linfonodos/virologia , Doença do Vírus de Marburg/transmissão , Doença do Vírus de Marburg/virologia , Marburgvirus/fisiologia , Replicação ViralRESUMO
The study of the preventive and therapeutic action of some immunomodulators (ridostin, reaferon and polyribonate) used alone and in combinations was conducted on laboratory animals infected aerogenically by Marburg or Ebola virus. It was found that special preventive intranasal and intramuscular administration of ridostin provided protection of the animals infected by Marburg virus (p = 0.1) and an increase in their mean lifespan by 2.4 days (p = 0.15). In the Ebola infection combined administration of ridostin and reaferon caused an essential increase in the mean lifespan of the animals by 2.9 days (p = 0.04). None of the tested drugs had any significant positive effect when used in various combinations according to the treatment schemes in Marburg and Ebola infections in guinea pigs.